Polymeric carriers for amphotericin B: In vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice

Journal of Antimicrobial Chemotherapy

Volumn 52, Issue 3, 2003, Pages 419-427

  Espuelas, M S ^a   Legrand, P ^b   Campanero, M A ^c   Appel, M ^b   Cheron M ^d   Gamazo, C ^e   Barratt, G ^b   Irache, J M ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIV PARIS SUD   (France)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d CNRS   (France)

^e UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Candida albicans; Micelles; Nanospheres; Poloxamer

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; FLUOROURACIL; NANOPARTICLE; POLOXAMER; POLYCAPROLACTONE; POLYENE; POLYMER; SURFACTANT;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG LIVER LEVEL; DRUG TRANSPORT; ERYTHROCYTE; FUNGUS ISOLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; KIDNEY CELL; KIDNEY TUBULE ABSORPTION; LD 50; MACROPHAGE; MICELLE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; QUANTITATIVE ASSAY;

EID: 0141629313     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg351     Document Type: Article

References (47)

1. Fridkin, S. K. & Jarvis, W. R. (1996). Epidemiology of nosocomial fungal infections. Clinical Microbiology Reviews 9, 499-511.
2. Garber, G. (2001). An overview of fungal infections. Drugs 61, Suppl. 1, 1-12.
3. Ellis, M. (2002). Invasive fungal infections: evolving challenges for diagnosis and therapeutics. Molecular Immunology 38, 947-57.
4. Pfaller, M. A. (1996). Nosocomial candidiasis: emerging species, reservoirs and modes of transmission. Clinical Infectious Diseases 22, Suppl. 2, S89-S94.
5. Rex, J. H., Walsh, T. J., Sobel, J. D. et al. (2000). Practice guidelines for the treatment of candidiasis. Clinical Infectious Diseases 30, 662-78.
6. Warnock, D. W. (1998). Fungal infections in neutropenia: current problems and chemotherapeutic control. Journal of Antimicrobial Chemotherapy 41, 95-105.
7. Brajburg, J. & Bolard, J. (1996). Carrier effects on biological activity of amphotericin B. Clinical Microbiology Reviews 9, 303-7.
8. Szoka, F. C. & Tang, M. (1993). Amphotericin B formulated in liposomes and lipid based systems: a review. Journal of Liposome Research 3, 363-75.
9. Van Etten, E. W. M., Otte-Lambillion, M., Van Vianen, W. et al. (1995). Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B desoxycholate (AmB-deoxycholate) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. Journal of Antimicrobial Chemotherapy 35, 509-19.
10. Van Etten, E. W. M., Chander, H. R., Snijders, S. V. et al. (1995). Interactions of liposomal amphotericin B with extracellular and intracellular Candida albicans. Journal of Antimicrobial Chemotherapy 36, 961-74.
11. Van Etten, E. W. M., Ten Kate, M. T., Stearne, L. E. T. et al. (1995). Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity and efficacy in systemic candidiasis in leukopenic mice. Antimicrobial Agents and Chemotherapy 39, 1954-8.
12. Van Etten, E. W. M., Snijders, S. V., Van Vianen, W. et al. (1998). Superior efficacy of liposomal amphotericin B with prolonged circulation in blood in the treatment of severe candidiasis in leukopenic mice. Antimicrobial Agents and Chemotherapy 42, 2431-3.
13. Van Etten, E. W. M., Van Vianen, W., Hak, J. et al. (1998). Activity of liposomal amphotericin B with prolonged circulation in blood versus those of AmBisome and AmB-deoxycholate against intracellular Candida albicans in murine peritoneal macrophages. Antimicrobial Agents and Chemotherapy 42, 2437-9.
14. Adler-Moore, J. & Proffitt, R. T. (2003). Effect of tissue penetration on AmBisome efficacy. Current Opinion in Investigational Drugs 4, 179-85.
15. Adler-Moore, J. & Proffitt, R. T. (2002). AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. Journal of Antimicrobial Chemotherapy 49, 21-30.
16. Bolard, J., Joly, V. & Yeni, P. (1993). Mechanism of action of amphotericin B at the cellular level. Its modulation by delivery systems. Journal of Liposome Research 3, 409-27.
17. Barwicz, J., Christian, S. & Gruda, G. (1992). Effects of the aggregation state of amphotericin B on its toxicity to mice. Antimicrobial Agents and Chemotherapy 36, 2310-5.
18. Legrand, P., Romero, E. A., Cohen, B. E. et al. (1992). Effect of aggregation and solvent on the activity of amphotericin B on human erythrocytes. Antimicrobial Agents and Chemotherapy 36, 2518-22.
19. Legrand, P., Cheron, M., Leroy, L. et al. (1997). Release of amphotericin B from delivery systems and its action against fungal and mammalian cells. Journal of Drug Targeting 4, 311-9.
20. Espuelas, M. S., Legrand, P., Irache, J. M. et al. (1997). Poly(E-caprolactone) nanospheres as an alternative way to reduce AmB toxicity. International Journal of Pharmaceutics 158, 19-27.
21. Espuelas, M. S., Legrand, P., Chéron, M. et al. (1998). Interaction of amphotericin B with polymeric colloids: 1. A spectroscopic study. Colloids and Surfaces B: Biointerfaces 11, 141-51.
22. Espuelas, M. S., Legrand, P., Chéron, M. et al. (1998). Interaction of amphotericin B with polymeric colloids: 2. Effect of poloxamer on the adsorption of amphotericin B onto poly(E-caprolactone) nanospheres. Colloids and Surfaces B: Biointerfaces 11, 203-12.
23. Espuelas, M. S., Campanero, M. A., Legrand, P. et al. (2000). Activity of AmB associated to polymeric carriers against Candida albicans in vitro and in a model of disseminated candidiasis in neutropenic mice. In Proceedings of the 27th International Symposium on Controlled Release of Bioactive Materials, Paris, 2000. Abstract 6131 pp. 335-6. Controlled Release Society Inc., Deerfield, IL, USA.
24. Campanero, M. A., Espuelas, M. S., Azanza, J. R. et al. (2000). Rapid determination of intramacrophagic amphotericin B by direct injection HPLC. Chromatographia 52, 827-30.
25. Rubio Calvo, M. C., Gil Tomas, J. & Ruesca, R. B. (1996). Valoracion in vitro de la sensibilidad a los antifungicos. Revista Iberoamericana de Micologia 13, S60-S63.
26. Graybill, J. R., Najvar, L. K., Fothergill, A. et al. (1998). KY-62, a polyene analog of amphotericin B, for treatment of murine candidiasis. Antimicrobial Agents and Chemotherapy 42, 147-50.
27. Wallace, T. L., Paetznick, V., Cossum, P. A. et al. (1997). Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrobial Agents and Chemotherapy 41, 2238-43.
28. Wasan, K. M. & Lopez Berestein, G. (1996). Characteristic of lipid-based formulations that influence their biological behaviour in the plasma of patients. Clinical Infectious Diseases 23, 1126-38.
29. Wasan, K. M. & Lopez Berestein, G. (1997). Diversity of lipid-based polyene formulations and their behaviour in biological systems. European Journal of Clinical Microbiology and Infectious Diseases 16, 81-92
30. Wasan, K. M., Kennedy, A. L., Cassidy, S. M. et al. (1998). Pharmacokinetic, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies. Antimicrobial Agents and Chemotherapy 42, 3146-52.
31. Gaboriau, F., Chéron, M., Petit, C. et al. (1997). Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index. Antimicrobial Agents and Chemotherapy 41, 2345-51.
32. Müllen, A. B., Carter, K. C. & Baillie, J. (1997). Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrobial Agents and Chemotherapy 41, 2089-92.
33. Costa, S. & Nucci, M. (2001). Can we decrease amphotericin nephrotoxicity? Current Opinion in Critical Care 7, 379-83.
34. Lamy-Freund, M. T., Schreier, S., Peitzsch, R. M. et al. (1991). Characterization and time dependence of amphotericin B:deoxycholate aggregation by quasielastic light scattering. Journal of Pharmaceutical Sciences 80, 262-6.
35. Barenholz, Y. & Cohen, R. (1995). Rational design of amphiphile-based drug carriers and sterically stabilized carriers. Journal of Liposome Research 5, 905-932.
36. Van Etten, E. W., van Vianen, W., Hak, J. et al. (2000). Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats. Antimicrobial Agents and Chemotherapy 44, 540-5.
37. Walsh, T. J., Yeldandi, V., Mcevoy, M. et al. (1998). Safety, tolerance, and pharmacokinetics of a small unilamellar formulation of Amphotericin B (AmBisome) in neutropenic patients. Antimicrobial Agents and Chemotherapy 42, 2391-8.
38. Boswell, G. W., Bekershy, I., Buell, D. et al. (1998). Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats. Antimicrobial Agents and Chemotherapy 42, 263-8.
39. Echevarría, I., Barturen, C., Renedo, M. et al. (2000). Comparative pharmacokinetics, tissue distributions and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats. Antimicrobial Agents and Chemotherapy 44, 898-904.
40. Moghimi, S. M. & Hunter, A. C. (2000). Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends in Biotechnology 18, 412-20.
41. Moghimi, S. M., Porter, C. J. H., Muir, I. S. et al. (1991). Nonphagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. Biochemical and Biophysical Research Communications 177, 861-6.
42. Moghimi, S. M. (1995). Mechanisms regulating body distribution of nanospheres conditioned with pluronic and tetronic block co-polymers. Advanced Drug Delivery Reviews 16, 183-93.
43. Bolard, J., Legrand, P., Heitz, F. et al. (1991). One-side action of amphotericin B on cholesterol-containing membranes is determined by its self-association in the medium. Biochemistry 30, 5707-15.
44. Brajtburg, J., Elberg, S., Schwartz, D. R. et al. (1985). Involvement of oxidative damage in erythrocyte lysis induced by amphotericin B. Antimicrobial Agents and Chemotherapy 27, 172-6.
45. Legrand, P., Vertut-Doi, A. & Bolard, J. (1996). Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line. Journal of Antimicrobial Chemotherapy 37, 519-33.
46. Watrous-Peltier, N., Uhl, J., Steel, V. et al. (1992). Direct suppression of phagocytosis by amphiphatic polymeric surfactants. Pharmaceutical Research 9, 1177-83.
47. Vertut-Doï, A., Ohnishi, S. & Bolard, J. (1994). The endocytic process in CHO cells, a toxic pathway of the polyene antibiotic amphotericin B. Antimicrobial Agents and Chemotherapy 38, 2373-9.